Fair access to drugs and the relationship between Big Pharma and public authorities in global health governance The essay aims to examine the relationship between public authorities and large transnational pharmaceutical companies from the perspective of access to drugs, focusing on the problems inherent to establishing the price of medicines. Furthermore, taking the European Union as an example of a supranational order, the article shows how pharmaceutical companies influence the pricing and reimbursement of drugs through existing regulations and why such legislation does not allow public authorities – national drug agencies – to set fair prices by facilitating access to a drug by European patients. Lastly, the study will analyse the remedies EU supranational law places at the disposal of the Court of Justice, European public authorities, and the Member States to counter the excessive pricing of drugs by multinational manufacturers and limit the undue influence of large companies.